Simon Read is CSO at Ra Pharmaceuticals, Inc. (RARX). They have made 7 open-market trades across 1 company since 2019, most recently 2026-08-19.
CIK 0001688199
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DNTH | SELL · 10b5-1 | 2026-08-19 | 2026-08-19 | $117.55 | $327K | -5.9% | -13.8% | — |
| DNTH | SELL · 10b5-1 | 2026-08-10 | 2026-08-11 | $109.55 | $304K | +1.3% | -5.8% | — |
| RARX | SELL | 2019-12-17 | 2019-12-18 | $47.08 | $471K | +0.0% | +0.1% | -4.6% |
| RARX | SELL | 2019-11-14 | 2019-11-18 | $46.68 | $467K | +0.0% | +0.4% | +0.0% |
| RARX | SELL | 2019-10-16 | 2019-10-17 | $46.87 | $469K | -0.2% | +0.0% | +0.6% |
| RARX | SELL | 2019-09-12 | 2019-09-16 | $25.41 | $254K | +0.6% | +88.4% | +90.2% |
| RARX | SELL | 2019-08-23 | 2019-08-27 | $27.77 | $278K | -8.2% | -8.9% | +70.8% |
| RARX | SELL | 2019-07-17 | 2019-07-18 | $32.95 | $330K | -1.5% | -15.8% | +35.6% |
| RARX | SELL | 2019-06-18 | 2019-06-19 | $22.23 | $435K | +36.6% | +38.4% | +5.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.